Novel MmpL3 Inhibitor as a Treatment of Mycobacterium Tuberculosis

 

Executive Summary

 

Mycobacterium Tuberculosis (Mtb) is the pathogen responsible for Tuberculosis. Standard TB treatments typically require four different drugs and a duration of six to nine months of treatment; however, there is still an evolution of drug-resistant Mtb. With not only Tuberculosis, but drug-resistant Tuberculosis causing upwards of 1.5 million deaths annually, there is a clear unaddressed need to develop novel drugs to combat TB. Our researchers at MSU have identified a molecule capable of killing TB when other drugs may not be able to. This drug has the potential to drastically improve the antibiotic cocktail currently administered to treat TB.

 

Description of Technology

 

A new class of MmpL3 inhibitors that has a distinct chemical structure and demonstrated abilities to kill Mycobacterium Tuberculosis. MmpL3 is a validated drug target that is essential for mTB’s cell viability. Now, MSU researchers have discovered new MmpL3 inhibitors which reduces mycolic acid biosynthesis of the Mycobacterium Tuberculosis ultimately killing the bacterium.

 

Key Benefits

•       MmpL3 chemical inhibitor

•       Small molecule drug targeting validated target

 

Applications

•       Enhancer of Mtb treatment

•       Reduce duration of treatment

 

Patent Status: 

 

Under Review.

 

Licensing Rights Available

 

Full licensing rights available.

 

Inventors: Robert Abramovitch, Huiqing Zheng

 

Tech ID: TEC2018-0055

 

Patent Information:

For Information, Contact:

SU-Jun Lim
Technology Manager
Michigan State University
limsuju1@msu.edu
Keywords: